The 67th American Society of Hematology (ASH) Annual Meeting & Exposition took place from December 6–9, 2025, in Orlando, Florida, offering both in-person and virtual participation. As the leading global forum for hematology, ASH 2025 brought together clinicians, researchers, and industry experts to present the latest advances in blood cancer research, benign hematologic disorders, emerging therapies, and clinical practice standards. The meeting featured high-impact scientific sessions, educational programs, late-breaking abstracts, and extensive industry exhibits, with core content made available online and on-demand through early 2026, ensuring broad access for the international hematology community.
25 Posts Not to Miss from ASH 2025
In this article, we selected 25 key posts you shouldn’t miss, capturing the most impactful insights, research updates, and expert perspectives shared throughout ASH 2025.
“ASH25 3+7 and Ivosidenib in newly diagnosed IDH1m AML Conclusion IVO-based induction, consolidation, and maintenance produced durable remissions, acceptable safety, and strong long-term survival. High response rates and reliable blood count normalization were observed, with nearly half of patients able to proceed to transplant. Outcomes were similar across treatment arms, and the regimen is now being tested in a phase 3 randomized trial. ”
“Dr. Emily Liang expertly presenting at ASH25 the largest study to date diving into the use of anakinra for refractory/severe ICANS (n=101). We benchmark key clinical outcomes, and identify potential predictive biomarkers of anakinra efficacy. Prospective comparative studies critically needed!”
“Long term outcomes of FL. 15y frorm diagnosis 60% of patients receiving ICT in 1L did not require 2L (curable disease?). And for all of us who favor observation in low tumor burden 1/3 of patients remain treatment free at 15y.”
“Sorial et al: time to relapse within 12mo (TTR12) as survival indicator in T-cell lymphoma – PETAL consortium, 452 pts & approx 300 for validn – Had to have CR to 1L Rx – TTR12 pts had worse OS irrespective of histology, PIT, prior ASCT Not surprising but useful.”
“Congratulations Dr Sueh-li Lim on side by side posters at ASH25 , Australasian Myeloma Research Consortium (AMaRC)
IBIS – Isatuximab, iberdomide, dexamethasone for FHR MM And Australasian Myeloma Research Consortium (AMaRC) FRAIL-M evaluating effective and deliverable lenalidomide and bortezomib backbone regimens in TI NDMM.”
“ASH25 Super special ASHKudos to the one-and-only Prof Ruben Mesa for receiving the prestigious Ernest Beutler Lecture & Prize for Lifetime Achievement in our MPN field !!!!”
“Excited to share our work at ASH! This is a bi-institutional study (UConn and Yale) on bone health in myeloma that has been recognized with ASH Abstract Achievement Award. Delays in dental screening is a major contributor to guideline nonadherence of bone-modifying agent (BMA) prescriptions. Opportunity for QI initiatives to streamline the process. Only around 56% of BMA prescriptions were fully concordant with the IMWG guidelines. The occurrence of skeletal events were also found to be similar between patients who received more than 5 years of BMA versus less than 5 years. This raises the question of whether prolonged use of BMA really confers benefit and further research is needed. Managing morbidities is as important as treating the malignancy itself. Sometimes this is what patients care about the most.”
“How to follow High Risk Smoldering Myeloma: Observation: If based on shared decision making you choose to follow without therapy this is what I would recommend for newly diagnosed patients: -Every 3 months blood work including M protein and FLC -Annual whole body CT or PET CT -If possible, annual MRI (whole body or spine/pelvis)(this was done in addition to annual CT/PET-CT in the AQUILA trial) The risk that progression will happen within 2 years while on observation is high ~50%. It’s important that this progression is not serious end organ damage. The above follow up was able to prevent serious end organ damage despite progression in AQUILA was precisely because the follow up was meticulous. On treatment: There is an FDA approved treatment, daratumumab. Personally, I would prefer clinical trial or Dara as default rather than observation. If patients are on Dara and responding well, I’ll follow similar to what I described for observation, but skip the annual MRI. You will hear more at ASH25 on AQUILA update based on various risk stratification models from Plasma Cell Pete”
“ASH25 US Multiple Myeloma Immunotherapy consortium We presented 14 orals, 8 posters at ASH! Now with 25+ sites Could never have imagined this success when Dr Hansen, Patel and I co-founded this 4+ years ago.”
“POEMS syndrome can be challenging to diagnose and treat. Angela Dispenzieri the world expert in this condition speaking at ASH25 on this condition. Joseph Mikhael chairing this scientific session.”
“Mayo, Harvard and now UPenn all independently reporting clinical dangers of Lymphopenia and how it affects survival in the last 2 months. Anktiva in combination with these treatments is the path to the change. NK and T cell counts matter and finally the clinical world is seeing.”
“Presenting at ASH25 in Orlando, FL
Deep dive through meta-analysis of clinical trials into Nivolumab & Pembrolizumab efficacy in r/r Hodgkin lymphoma subgroups, call to move for more personalized approach.
Thank you, American Society of Hematology for Abstract Achievement Award
Thankful co-authors for their contributions”
“ASH25 honored that our team at Atrium Health Wake Forest Baptist Comprehensive Cancer Center part of the exciting results of CALR mAB in essential thrombocythemia demonstrating control of platelets, molecular response and bone marrow morphology! Vikas Gupta Incyte Wake Forest University School of Medicine Advocate Health”
“Checklist for ASH25
Get to beFight4Hematology superhero
Cuddle time with Puppies
Reconnect with my Hematology community
Conferences can be busy running between meetings and sessions (think about step count ). I’m really grateful for American Society of Hematology for creating spaces to also have some fun and take a moment to be Present with what is most important.
Enjoying small moments with Eva Flahavan & Emilie Prazakova at ASH25”
“As ASH25 winds down, incredibly proud of the Bristol Myers Squibb medical team for showing up strong and supporting a phenomenal lineup up presentations and engagements! And the booth was ! Thank you all!
Leland Laury Tania Small, MD Monica Shaw Adam Lenkowsky Pei-Ran Ho Kimberly (Kim) Blanchard Portland, Ph. D. Shalon M. Jones, PharmD, MPH Jenine Anday Sanzari Mecide Gharibo Teresa Peluso Michael Sturniolo, PhD Erin Jungryun Ahn, MD”
“Like everything else good in life .. ASH25 must also come to an end! Congrats to Dr. Belinda Avalos and American Society of Hematology on this huge success! I’m exhausted but my heart & brain are full! To my wonderful hematology friends & colleagues: 4 welcoming this pathologist into your community! See U all at ASH26 in NOLA ”
“Proud of Nilesh Kapoor and Alex Li for their ASH25 Abstract Achievement Award poster presentations! Incredible work in collaboration with the Marrow Consortium Ak Eisfeld. Huge congratulations to both! ”
“ASH25 AZA/VEN plus TAG in newly diagnosed in RR BPDCN presented by Dr. Andy Lane. ”
“In MajesTEC-3, only 5% pts were CD38 exposed and none were CD38 Refractory. For a SOC U.S. pt progressing on D+R, I am not sure if adding Tec to Dara will have the same punch. On the contrary, ~20% in CARTITUDE-4 were CD38 refractory and had similar benefit from cilta-cell.”
“Phoebe Joy Ho presents at LBA ASH25 first 4 RRMM patients treated with KLN-1010, a modified lentiviral vector generating anti-BCMA CAR-T in vivo CAR-T expansion without LD All patients achieved early MRD neg No significant early safety concerns Looking forward to more data!”
“Unprecedented. ASH25 Tec-Dara in relapsed myeloma.”
“Dr. Hanny Al-Samkari ASH25 LBA on VAYHIT2 (randomized, double-blind, Ph 3 of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with ITP who failed first-line corticosteroids. Short course of iana+eltrombo induced durable disease control, well tolerated.”
“Most trials will require MRD assessments once CR is achieved. Median time to MRD negativity should be reported in all trials & can serve as a guide to stop Rx in those VGPR/CR pts who don’t want BM MRD. In CAR T-4, MRD neg pts had 90% probability of being progression free at 3yr. In MAJ-3, almost all of ‘evaluable’ pts were MRD neg, so hard to tell if MRD+ had risk of relapse if stopped Rx”
“ASH25 Practice-changing update in AL amyloidosis. GLS imperative for AL-ISS staging, prognostication, and (?) cardiac responses some day. But echocardiographer has to know to track speckles. If first TTE omitted GLS, worth repeating it! ( awechalekar
– excellent work!)”
“A sincere thank you to ASH faculty and staff for an amazing ASH25! Stats from X: 91.4 million impressions 14,300+ posts 3,000+ participants An AMAZING meeting in Orlando!”
15 Posts Not to Miss from ASH 2025, Part 1
20 Posts Not to Miss from ASH 2025, Part 2
Written by Nare Hovhannisyan, MD